Skip to main content

Medical Marijuana

Press Release: National Boards of Pharmacy Conference Focuses on Medical Marijuana

FOR IMMEDIATE RELEASE: December 3, 2009 CONTACT: ASA Media Liaison Kris Hermes at 510-681-6361 National Boards of Pharmacy Conference Focuses on Medical Marijuana Advocacy Group Presents on Medical Marijuana Alongside AMA & Other Health Experts Tucson, AZ -- As pharmacists and drug regulators from across the country convene in Tucson this week for their Winter symposium, they will be discussing medical marijuana, an issue which is headlining the agenda. The National Association of Boards of Pharmacy (NABP) opens its symposium on Thursday with several presentations on medical marijuana by an array of speakers and experts, including Caren Woodson, Government Affairs Director with Americans for Safe Access, the country's largest advocacy organization focused on the issue. "We welcome the interest in medical marijuana by the Boards of Pharmacy and want to work with them to address this public health issue," said Woodson. "State Boards of Pharmacy can have an impact on medical marijuana and we want to work with them to adopt sensible policies." The Oregon Board of Pharmacy has been ordered to remove marijuana from its state list of Schedule I drugs, per legislation signed by Governor Kulongoski in August. In addition, the Iowa Board of Pharmacy is currently considering rescheduling marijuana as a result of litigation. Woodson will co-present on a panel Thursday morning with Barry D. Dickinson, the Director of Science & Biotechnology for the American Medical Association, and Alice Mead, the Director of U.S. Public Relations for GW Pharmaceuticals, a U.K. company conducting clinical trials for a medical marijuana extract. The panel is entitled, "Should Marijuana be a Medical Option?" Later, Woodson will take part in a point-counterpoint on medical marijuana with Dickinson, Mead and other experts, including Andrea Barthwell, former deputy director for the U.S. Office of National Drug Control Policy and other marijuana researchers. The NABP symposium will be attended by Boards of Pharmacy executive officers, members, and other state and federal regulators as well as stakeholders in the pharmaceutical industry. Both the California Attorney General's office and the California Department of Public Health are sending representatives to the symposium. Attendees will be able to earn continuing pharmacy education credit for their participation in medical marijuana panels. The mission of the NABP is to assist its member boards in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health. The State Boards of Pharmacy oversee the classification of controlled substances, such as marijuana, at the state level, similar to the way that the Food & Drug Administration (FDA) and the Drug Enforcement Administration (DEA) oversee the federal classification of controlled substances. While state controlled substance lists routinely match the federal list, the State Boards of Pharmacy can change the classification of particular drugs independent of the federal government. The NABP symposium follows a report on medical marijuana issued last month by the American Medical Association, in which the oldest and largest physician-based group in the U.S. urged the federal government to review the Schedule I status for marijuana. The AMA noted that marijuana appeared to be efficacious for several health conditions and said that further research was needed to assess whether marijuana should continue to be considered a dangerous drug with no medical value. Further Information: The National Association of Boards of Pharmacy 2009 Symposium Schedule: http://www.nabp.net/whatsnew/meetings/2009symposium/ ASA National Policy Platform: http://www.safeaccessnow.org/downloads/ASA_Natl_Policy_Agenda_09-11.pdf # # #

Congress is starting to listen...

Dear friends:

I wanted to say thank you to Sioux Colombe, an ASA Ambassador in Sacramento, California.  The email she received below demonstrates that Congress is starting to hear us.

Sioux had asked her Member of Congress, Representative Doris Matsui, to support the Truth in Trials Act.  Sioux got the response below, which is a perfect example of the kind of dialog we want to build with our elected officials.

This reply means that Rep. Matsui's office took the time to research the Truth in Trials Act and respond.  The next step is to ask Rep. Matsui to become a supporter -- a "cosponsor" -- of the bill.

Will you do the same for your U.S. Representative? 

If your Rep gets a phone call from you, they will start paying attention.

Here's what you have to do -- it will take 5 minutes.

1. Find out who your Rep is.  Go to http://www.house.gov and type in your zip code in the upper left corner.  If it asks for your full "Zip+4", just look at your last piece of junk mail.

2. Dial 202-224-3121.  Ask the operator to transfer you to your Member of Congress.

3. Tell your Rep ... "I'm calling from ______ and I want you to cosponsor HR 3939, the Truth in Trials Act."

4. Reply to this email and tell me who you called.

Thanks!

- Sanjeev, ASA

P.S.  The full email that Sioux received is below.


Sanjeev Bery
National Field Director
Americans for Safe Access


----- Forwarded Message ----
From: Congresswoman Doris O. Matsui
To: Sioux Colombe
Sent: Tue, December 1, 2009 12:22:29 PM
Subject: From the Office of Congresswoman Matsui

December 1, 2009 
 

Ms. Sioux Colombe
Sacramento, California

Dear Sioux:

Thank you for contacting me regarding medical marijuana.  I appreciate hearing from you on this issue.

As you may know, 13 states, including California, currently allow the use of marijuana for medical purposes.  In these jurisdictions, state-level penalties for the cultivation, possession, and use of medical marijuana have been removed, and programs to regulate patients' use have been established or are currently being considered.  However, in these 13 states where medical marijuana use is legal, users remain subject to federal penalties for such use.

In an effort to correct this, legislation has been introduced in the 111th Congress to permit the use of medical marijuana under federal law in states where marijuana is currently being used for medicinal purposes.  The Medical Marijuana Patient Protection Act (H.R. 2835), would achieve this end by re-classifying marijuana into a less restrictive category of drug under the regulatory structure of the Controlled Substances Act.

Another piece of legislation, the Truth in Trials Act (H.R. 3939), responds to the Justice Department's directive on medical marijuana policy, which tells federal prosecutors to avoid pursuing cases against individuals who legally use medical marijuana.  Specifically, H.R. 3939 would allow a person on trial for a federal marijuana-related offense to introduce evidence that the alleged marijuana-related activities were performed in compliance with state laws.

Again, thank you for taking the time to contact me regarding medical marijuana.  To learn more about my work in Congress, or to sign up for occasional e-mail updates, please visit my website at http://matsui.house.gov.


Sincerely,


DORIS O. MATSUI
Member of Congress

Patients Out of Time: Announcing a New Look

Announcing a new look to http://www.MedicalCannabis.com/ Patients Out of Time is pleased to notify the professional health care community of the most unique educational platform for the exploration of medicinal cannabis (marijuana) science in the United States. This site provides visitors with a wide array of information related to the efficacy of cannabis as medicine. Links are provided to the faculty and agendas of five past accredited clinical conferences and to Google video and You Tube video of over 50 academic presentations of world-wide cannabis related science. A link is provided for registration for media, exhibitors, health care professionals and the public for The Sixth National Clinical Conference on Cannabis Therapeutics to be held April 15-17, 2010 in Warwick (Providence), RI. The forum is co-sponsored by Patients Out of Time, the School of Medicine, University of California San Francisco , the Rhode Island State Nurses Association, and the Rhode Island Patient Advocacy Coalition (RIPAC). The forum will be located at the Crowne Plaza Hotel at the Crossings. Medical Doctors and Registered Nurses will also find continuing medical education credits (CME's) or continuing education contact hours available "on-line" that are based on clinical research conducted world-wide on the cannabis plant. These credits, authorized by the American Nurses Association and the American Medical Association are provided by the UCSF School of Medicine, Office of Continuing Education through a direct link on the web site. Journalists and other media representatives are advised to seek the opinion of medical professionals of great expertise in therapeutic cannabis treatments and the interpretation of new cannabis science rather than the traditional sources of cannabis information which are staffed by administrators and lobbyists, not medical professionals. The four United States federally supplied cannabis patients, medical doctors and registered nurses are available for interview or consultation with Patients Out of Time. Contact: Al Byrne, Co-founder Patients Out of Time, 501c3 educational charity 1472 Fish Pond Rd. Howardsville, VA 24562 E-mail: [email protected] Tel: (434) 263-4484 Fax: (434) 263-6753

Landmark Medical Marijuana Hearings Tomorrow in Harrisburg

FOR IMMEDIATE RELEASE

Pennsylvanians for Medical Marijuana

www.pa4mmj.org 

WHO: Pennsylvania House Health and Human Services committee

WHAT: Public Hearings on HB 1393, medical marijuana in PA

WHEN: December 2, 2009 Room 140 at 11AM, Main Capitol in Harrisburg

CONTACT: Chris Goldstein cellphone 505 577 5093 or email [email protected]

**UPDATE**

A Press Conference with Rep. Cohen and PA4MMJ patients will take place at 10:00AM at the East Rotunda

 

Landmark Medical Marijuana Hearings Tomorrow in Harrisburg

December 1, 2009

Philadelphia- Advocates and patients with the group Pennsylvanians for Medical Marijuana (PA4MMJ) will testify tomorrow before the PA House of Representatives Health and Human Services Committee during hearings on HB 1393, The Compassionate Use Medical Marijuana Act.

 

These will be the first public hearings on medical cannabis in the history of the Commonwealth.

On April 29, 2009 Rep. Mark B. Cohen introduced the bill to legalize medical marijuana with PA4MMJ. HB1393 would allow registered patients to grow six plants or purchase cannabis through Compassion Centers. A provision in the bill allows these medical cannabis sales to be taxed.

At a press conference at the bill’s introduction Cohen said, "It's time to create a new, honest image for marijuana. One as a form of treatment that when prescribed by responsible doctors could help thousands of patients across this commonwealth."

Three newspaper Editorial Boards endorsed the bill immediately after it was introduced: The Philadelphia Inquirer, The Pocono Record and the Daily Review of Towanda.

 

Testifying in favor of the bill: Chris Goldstein and Derek Rosenzweig of PA4MMJ; Ed Pane of Serento Gardens Treatment Center; Bradley Walter who lives with HIV; Andrew Hoover of the ACLU-PA, Criminal Defense Attorney Patrick Nightengale; MS patient John Wilson of New Jersey; Brian Gralnick of JSPAN; Bob Ceppecio of The Marijuana Policy Project along with other local patients and professionals. Signed written testimony from 26 PA residents will be presented by PA4MMJ along with 19 written submissions sent anonymously. Expert written submissions and comments came from the AIDS Law Project of Pennsylvania, the National Lawyers Guild Philadelphia Chapter, The Coalition for Medical Marijuana New Jersey and the National Organization for the reform of Marijuana Laws Deputy Director Paul Armentano.

Several groups will testify in opposition to medical cannabis including the PA Elks Association.

The December 2nd hearings are informational and will not see a vote. The twenty-six-member committee may ask questions of the presenters and PA4MMJ is expecting a lively and educational discussion. Please visit www.pa4mmj.org

MEDIA MAY CONTACT CHRIS GOLDSTEIN DIRECTLY [email protected]

Help put medical marijuana on the ballot in Arizona

Dear friends:

We’re getting close.

In Arizona, an MPP-sponsored signature drive to place a medical marijuana initiative on the ballot in November 2010 is moving into the home stretch. If the campaign collects more than 250,000 signatures before the end of February, the Arizona Medical Marijuana Policy Project could qualify for the ballot earlier in the election year than any other initiative in Arizona’s history.

As of now, the campaign has collected more than 175,000 signatures, almost three-quarters of the way towards our goal. But it costs about $2 to collect each signature, so we need help to get the rest of the way there.

Can you help us finish the job by making a contribution to the campaign today? Every $20 contribution gets us 10 signatures closer to our goal.

A recent poll showed that 65% of Arizonans support the proposed initiative, so once the measure qualifies for the ballot, it will very likely pass. This means that by supporting this signature drive, you can directly help protect seriously and terminally ill patients in Arizona from arrest and jail. The initiative, which would allow for a system of state-licensed medical marijuana dispensaries in the state, could also serve as a model for other states considering medical marijuana laws.

I know you agree that patients should never be sent to jail just for following their doctors’ advice. With a contribution today, you can help make sure medical marijuana patients in Arizona don’t have to fear this fate.

Thanks in advance for your support. And whether or not you are able to make a contribution today, please forward this e-mail to anyone who might be interested in this campaign.

Thank you,

Rob's signature

Rob Kampia
Executive Director
Marijuana Policy Project
Washington, D.C.

P.S. As I've mentioned in previous alerts, a major philanthropist has committed to match the first $2.35 million that MPP can raise from the rest of the planet in 2009. This means that your donation today will be doubled.

BREAKING: A Legal Victory for Patients


BREAKING:  Legal Victory for Patients and Providers

 

This morning, Sensible Colorado attorneys delivered a victory in overturning the Board of Health's 10/19/9 decision which limited patients rights.   See coverage of this story HERE

As background, late on Monday Nov. 2, Sensible Colorado received word that the state was holding a stealth meeting to narrow the definition of who could provide medical marijuana.  Our staff immediately sent out an alert and over 200 of our supporters responded by either calling-in or attending the Board's 11/3 meeting.  At that meeting, after refusing to hear from any affected patients or caregivers, the Board voted to require caregivers to provide supplementary-- and often unnecessary services-- beyond supplying medical marijuana to sick patients.

Today, Sensible Colorado Board member Robert Corry, along with staff member Brian Vicente, and attorney Lauren Davis, successfully argued that the 11/3 "stealth" meeting was a violation of the Colorado Open Meetings Law.  After hearing about the state's complete disregard for public testimony and their lack of notice to affected parties, Chief Denver District Chief Larry Naves ruled in favor of patients and invalidated the Board's recent finding.

Sensible Colorado wants to thank the two patients involved in this lawsuit, as well as the hundreds of patients and supporters who attended-- or tried to attend-- these hearings. 

What does this mean for patients and providers?  Judge Naves ruling means that, under Colorado law, medical marijuana caregivers can continue to simply provide medical marijuana for patients and are not required to provide supplementary services.  Please stay tuned for further alerts, as this area of the law is dynamic.

We can't do this without your help!!  Please support the work of Sensible Colorado by becoming a monthly donor today.  Click HERE to help.

Press Release: AMA Report Recognizes Medical Benefits of Marijuana, Urges Further Research

PRESS RELEASE Americans for Safe Access For Immediate Release: November 10, 2009 AMA Report Recognizes Medical Benefits of Marijuana, Urges Further Research Largest and oldest U.S. physician-based group reverses long-held position on medical marijuana Houston, TX -- The American Medical Association (AMA) voted today to reverse its long-held position that marijuana be retained as a Schedule I substance with no medical value. The AMA adopted a report drafted by the AMA Council on Science and Public Health (CSAPH) entitled, "Use of Cannabis for Medicinal Purposes," which affirmed the therapeutic benefits of marijuana and called for further research. The CSAPH report concluded that, "short term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis." Furthermore, the report urges that "the Schedule I status of marijuana be reviewed with the goal of facilitating clinical research and development of cannabinoid-based medicines, and alternate delivery methods." The change of position by the largest physician-based group in the country was precipitated in part by a resolution adopted in June of 2008 by the Medical Student Section (MSS) of the AMA in support of the reclassification of marijuana's status as a Schedule I substance. In the past year, the AMA has considered three resolutions dealing with medical marijuana, which also helped to influence the report and its recommendations. The AMA vote on the report took place in Houston, Texas during the organization's annual Interim Meeting of the House of Delegates. The last AMA position, adopted 8 years ago, called for maintaining marijuana as a Schedule I substance, with no medical value. "It's been 72 years since the AMA has officially recognized that marijuana has both already-demonstrated and future-promising medical utility," said Sunil Aggarwal, Ph.D., the medical student who spearheaded both the passage of the June 2008 resolution by the MSS and one of the CSAPH report's designated expert reviewers. "The AMA has written an extensive, well-documented, evidence-based report that they are seeking to publish in a peer-reviewed journal that will help to educate the medical community about the scientific basis of botanical cannabis-based medicines." Aggarwal is also on the Medical & Scientific Advisory Board of Americans for Safe Access (ASA), the largest medical marijuana advocacy organization in the U.S. The AMA's about face on medical marijuana follows an announcement by the Obama Administration in October discouraging U.S. Attorneys from taking enforcement actions in medical marijuana states. In February 2008, a resolution was adopted by the American College of Physicians (ACP), the country's second largest physician group and the largest organization of doctors of internal medicine. The ACP resolution called for an "evidence-based review of marijuana's status as a Schedule I controlled substance to determine whether it should be reclassified to a different schedule. "The two largest physician groups in the U.S. have established medical marijuana as a health care issue that must be addressed," said ASA Government Affairs Director Caren Woodson. "Both organizations have underscored the need for change by placing patients above politics." Though the CSAPH report has not been officially released to the public, AMA documentation indicates that it: "(1) provides a brief historical perspective on the use of cannabis as medicine; (2) examines the current federal and state-based legal envelope relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding of the pharmacology and physiology of the endocannabinoid system; (4) reviews clinical trials on the relative safety and efficacy of smoked cannabis and botanical-based products; and (5) places this information in perspective with respect to the current drug regulatory framework." Further information: Executive Summary of AMA Report: http://AmericansForSafeAccess.org/downloads/AMA_Report_Executive_Summary.pdf Recommendations of AMA Report: http://AmericansForSafeAccess.org/downloads/AMA_Report_Recommendations.pdf American College of Physicians resolution: http://www.acponline.org/advocacy/where_we_stand/other_issues/medmarijuana.p df # # # With over 30,000 active members in more than 40 states, Americans for Safe Access (ASA) is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and the caregivers.

AMA Calls for Review of Medical Marijuana’s Legal Status

FOR IMMEDIATE RELEASE                                                                                           
NOVEMBER 10, 2009

AMA Calls for Review of Medical Marijuana’s Legal Status

New Policy Marks Historic Shift From Prior Stance

CONTACT: Bruce Mirken, MPP director of communications …………… 415-585-6404 or 202-215-4205

HOUSTON, TEXAS — In a move considered historic by supporters of medical marijuana, the American Medical Association’s House of Delegates today adopted a new policy position calling for the review of marijuana’s status as a Schedule I drug in the federal Controlled Substances Act. The old language in Policy H-95.952 had previously recommended that “marijuana be retained in Schedule I,” which groups marijuana with drugs such as heroin, LSD and PCP that are deemed to have no accepted medical uses and to be unsafe for use even under medical supervision.

         The revised policy, adopted today, states, “Our AMA urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods.” It goes on to explain that this position should not be construed as an endorsement of state medical marijuana programs.

         “This shift, coming from what has historically been America’s most cautious and conservative major medical organization, is historic,” said Aaron Houston, director of government relations for the Marijuana Policy Project, who attended the AMA meeting. “Marijuana’s Schedule I status is not just scientifically untenable, given the wealth of recent data showing it to be both safe and effective for chronic pain and other conditions, but it’s been a major obstacle to needed research.”

         Drugs listed in Schedule II, for which medical use is permitted with strict controls, include cocaine, morphine and methamphetamine. A pill containing THC, the component responsible for marijuana’s “high,” is classed in Schedule III, whose looser requirements allow phoned-in prescriptions.

         With more than 29,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Maine Votes “Yes” on Medical Marijuana Dispensaries

FOR IMMEDIATE RELEASE                                                                                             
NOVEMBER 3, 2009

Maine Votes “Yes” on Medical Marijuana Dispensaries,

Becomes 3rd State to License Medical Marijuana Providers; Vote Seen as Latest Advance Spurred by Obama Policy

CONTACT: Bruce Mirken, MPP director of communications …………… 415-585-6404 or 202-215-4205

AUGUSTA, MAINE — In a landmark vote, Maine voters today approved Question 5, making the state the third in the country to license nonprofit organizations to provide medical marijuana to qualified patients and the first ever to do so by a vote of the people. With 49 percent of the vote tallied, the measure was cruising to an easy win with 60.2 percent voting “yes” and 39.8 percent voting “no.”

         Under the measure, the state will license nonprofit organizations to provide medical marijuana to qualified patients and set rules for their operation. While 13 states permit medical use of marijuana, only Rhode Island and New Mexico have similar dispensary provisions, both of which were adopted by the states’ legislatures. Maine’s original medical marijuana law was passed in 1999.

         “This is a dramatic step forward, the first time that any state’s voters have authorized the state government to license medical marijuana dispensaries,” said Rob Kampia, executive director of the Marijuana Policy Project in Washington, D.C., which drafted the initiative and provided start-up funding for the campaign. “Coming a decade after passage of Maine’s original marijuana law, this is a huge sign that voters are comfortable with these laws, and also a sign that the recent change of policy from the Obama administration is having a major impact.”  

         In October, the U.S. Department of Justice issued a formal policy indicating that federal prosecutors should not prosecute medical marijuana activities authorized by state law.

         Question 5 also expands the list of medical conditions qualifying for protection under Maine’s law to include several conditions that are included in most other medical marijuana states, including intractable pain, agitation of Alzheimer’s disease, and amyotrophic lateral sclerosis (“Lou Gehrig’s disease”).

         With more than 29,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Subscribe to Medical Marijuana